Drugs / Esomeprazole
Esomeprazole
also known as
Nexium · esomeprazole magnesium · HIP1601 · D961H · Dermaprazole · Esomeprazole magnesium dihydrate · esomeprazole magnesium trihydrate · Esomeprazole Sodium · +14 more
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | NEXIUM IV | — | 2011-04-29 – 2014-03-04 | fda.gov ↗ |
| Approved | EU (EMA) | Nexium Control | — | 2013-08-26 | europa.eu ↗ |
| Label expansions (5) | US (FDA) | NEXIUM | — | 2004-11-24 – 2011-12-15 | fda.gov ↗ |
| Approved | US (FDA) | NEXIUM | — | 2001-02-20 | fda.gov ↗ |
Trials 272 · started per year
today
US approved 2001
EU approved 2013
1
9
13
9
11
14
19
19
17
8
10
7
5
10
9
7
11
10
9
14
8
10
9
9
13
7
3
2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 171 trials | ||||||
| Phase 1 | NCT07294846 | Sep → Dec 2025 | — | Jiangsu Sinorda Biomedicine Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT07018635 | Jul → Sep 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06793943 | Jan → Mar 2025 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT06733675 | Jan 2025 → Dec 2026 expected | — | Basilea Pharmaceutica | Recruiting | No outcome recorded |
| Phase 1 | NCT06717269 | Nov 2024 → Apr 2026 overdue | — | Nurix Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06233149 | Oct → Nov 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06233097 | Aug → Sep 2024 | — | Bio-innova Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT06419660 | May → Jul 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06366243 | May → Jun 2024 | — | Cerevel Therapeutics, LLC | Completed | No outcome recorded |
| Phase 1 | NCT06378658 | Mar → Jun 2024 | non-small cell lung carcinoma | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT06213818 | Mar 2024 → Aug 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06275841 | Feb → May 2024 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT06193811 | Jan → Mar 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT06164834 | Dec 2023 → Nov 2024 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT05845645 | May 2023 → Apr 2024 | — | UCB Biopharma SRL | Completed | No outcome recorded |
| Phase 1 | NCT05826574 | May → Jul 2023 | — | Insmed Incorporated | Completed | No outcome recorded |
| Phase 1 | NCT05232994 | Mar 2023 → Dec 2024 | severe pre-eclampsia | Christiana Care Health Services | Unknown | No outcome recorded |
| Phase 1 | NCT05688124 | Feb → Oct 2023 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05586568 | Nov 2022 → Apr 2023 | — | Xuanzhu Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05467475 | Oct 2022 → Jan 2023 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT05061563 | Sep → Dec 2021 | — | Bayer | Completed | No outcome recorded |
| Phase 1 | NCT04942652 | Jul → Aug 2021 | achlorhydria | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT04568772 | Nov 2020 → Jul 2021 | gastroesophageal reflux disease | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT05513625 | Jul → Oct 2020 | herpes simplex infectious disease | AiCuris Anti-infective Cures AG | Completed | No outcome recorded |
| Phase 1 | NCT04468815 | Jul → Oct 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04324905 | Apr → Oct 2020 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT04204629 | Jan → Feb 2020 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT04156646 | Nov → Dec 2019 | autism spectrum disorder | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT04142762 | Oct 2019 → Jan 2020 | chronic hepatitis B virus infection | Assembly Biosciences | Completed | No outcome recorded |
| Phase 1 | NCT04138836 | Sep → Nov 2019 | — | Bridge Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03978143 | Jun → Oct 2019 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03980756 | Jun 2019 → Apr 2020 | gastritis | Addpharma Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03882112 | Apr → Aug 2019 | — | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1 | NCT03708211 | Mar → Dec 2019 | neoplasm | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03849690 | Feb → Apr 2019 | — | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03814642 | Jan → Jul 2019 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03372850 | Feb → Jun 2018 | — | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
| Phase 1 | NCT03383042 | Dec 2017 → Nov 2018 | active peptic ulcer disease | Jeil Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03558477 | Sep 2017 → Feb 2018 | gastroesophageal reflux disease | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03211143 | Jun → Aug 2017 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT03137134 | Jun → Sep 2017 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT03127046 | Mar → Apr 2017 | — | Dong Wha Pharmaceutical Co. Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT02361619 | Feb 2015 → Sep 2016 | — | Turku University Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02128893 | Jan → Feb 2014 | — | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02023125 | Dec 2013 → Mar 2014 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT01964131 | Oct → Dec 2013 | duodenal ulcer, gastric ulcer, peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01844583 | Jun 2013 → Aug 2014 | cancer, lymphoma | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01761513 | Nov 2012 → Feb 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01549574 | May 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01358383 | May → Jun 2011 | juvenile idiopathic arthritis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01210339 | Nov 2010 → Aug 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01163630 | Jun → Sep 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01147588 | May 2010 → May 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01135472 | Mar 2010 → Apr 2012 | — | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT01094483 | Mar → May 2010 | platelet aggregation, spontaneous | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00942175 | Dec 2009 → Jun 2010 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00963027 | Sep → Oct 2009 | pulmonary arterial hypertension | United Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT00992381 | Sep → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00849329 | Mar → Nov 2009 | breast neoplasm | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1 | NCT00692055 | Jun → Jul 2008 | arthritic joint disease | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00676442 | May → Jun 2008 | arthritic joint disease | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00676117 | Apr → Jul 2008 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00688428 | Apr 2008 | dyspepsia, ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00684190 | Mar → Jun 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00665743 | Mar → Jun 2008 | arthritic joint disease | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00599404 | Jan → Feb 2008 | — | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT02141698 | Oct 2007 → Feb 2008 | — | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT00474019 | Oct 2007 → Oct 2009 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00687245 | Aug 2006 → May 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00216788 | Jan 2006 | Barrett esophagus, esophagitis, gastroesophageal reflux disease | Main Line Health | Unknown | No outcome recorded |
| Phase 1 | NCT01820143 | Feb → Apr 2005 | — | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06302049 | Jun 2024 → May 2025 | metabolic dysfunction-associated steatohepatitis | Sadat City University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05269160 | Apr → Jun 2023 | breast cancer, radiodermatitis | Baylor College of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT02473640 | Jun 2015 → Apr 2016 | — | Theriva Biologics, Inc. | Completed | No outcome recorded |
| Phase 210 trials | ||||||
| Phase 2 | NCT06120803 | Mar 2024 → Dec 2027 expected | non-small cell lung carcinoma, radiation-induced disorder | Rush University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04865731 | Jun 2022 → Jun 2024 | head and neck cancer | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 2 | NCT03488147 | Jul 2020 | arthropathy, gastroesophageal reflux disease | Icahn School of Medicine at Mount Sinai | Withdrawn | No outcome recorded |
| Phase 2 | NCT03866668 | May 2019 → Dec 2028 expected | autism | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT02743949 | Jul 2016 → Oct 2018 | gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 2 | NCT01069081 | Aug 2009 → Feb 2012 | breast cancer, metastatic neoplasm | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT00723502 | Sep 2008 → Apr 2009 | Helicobacter pylori infectious disease, dyspepsia | MerLion Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 2 | NCT00405119 | May 2006 → Mar 2007 | gastroesophageal reflux disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT00317044 | Apr 2006 → Jul 2008 | asthma, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT00628953 | Oct 2002 → Apr 2004 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT05297695 | Apr 2022 → Oct 2023 | Helicobacter pylori infectious disease, generalized epilepsy | Sohag University | Completed | No outcome recorded |
| Phase 2/3 | NCT05861687 | Aug → Dec 2021 | Helicobacter pylori infectious disease | Finni Kollins | Completed | No outcome recorded |
| Phase 2/3 | NCT03213639 | Mar 2018 → Jul 2020 | preeclampsia | Assiut University | Completed | No outcome recorded |
| Phase 2/3 | NCT01089959 | Mar 2010 → Mar 2012 | gastroesophageal reflux disease | Southern Arizona VA Health Care System | Unknown | No outcome recorded |
| Phase 361 trials | ||||||
| Phase 3 | NCT06811207 | Feb 2025 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT06101420 | Jan 2022 → Jun 2023 | — | Ain Shams University | Completed | No outcome recorded |
| Phase 3 | NCT05024721 | Aug 2021 → Mar 2022 | gastritis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT04696783 | Jul → Sep 2021 | gastroesophageal reflux disease | Fifth Affiliated Hospital, Sun Yat-Sen University | Unknown | No outcome recorded |
| Phase 3 | NCT03452865 | Jan 2020 → Aug 2023 | infectious disease with sepsis | Vita-Salute San Raffaele University | Completed | No outcome recorded |
| Phase 3 | NCT04325620 | Jun 2019 → Aug 2020 | gastroesophageal reflux disease | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT03967886 | Apr → Dec 2019 | gastroesophageal reflux disease | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03717740 | Dec 2018 → Nov 2021 | preeclampsia | Aswan University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04080726 | Oct 2018 → Dec 2019 | gastroesophageal reflux disease | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 3 | NCT03148366 | Feb 2015 → Dec 2019 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT02157376 | Jul 2014 → Feb 2016 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02037477 | Jan → Mar 2014 | — | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT01757275 | Feb 2013 → Dec 2014 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01669811 | Aug 2012 → May 2014 | peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01370538 | Aug → Oct 2011 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01370525 | Aug → Oct 2011 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01544517 | Jan → May 2011 | Helicobacter pylori infectious disease | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase 3 | NCT01069939 | Feb 2010 → Nov 2011 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00664560 | Apr → Dec 2008 | osteoarthritis | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00665431 | Apr → Dec 2008 | osteoarthritis | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00567658 | Feb 2008 → Jan 2010 | laryngeal disorder | Vanderbilt University | Withdrawn | No outcome recorded |
| Phase 3 | NCT00634114 | Jan 2008 → May 2009 | esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00633932 | Dec 2007 → Dec 2008 | peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00595517 | Oct 2007 → Sep 2009 | duodenal ulcer, gastric ulcer, lumbar disk disease, osteoarthritis +1 | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT01129011 | Sep 2007 → Sep 2008 | gastric ulcer | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00594854 | Sep 2007 → Sep 2008 | gastric ulcer | POZEN | Terminated | No outcome recorded |
| Phase 3 | NCT00527787 | Sep 2007 → Oct 2008 | gastric ulcer | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00542789 | Aug 2007 → Feb 2009 | duodenal ulcer, gastric ulcer, lumbar disk disease, osteoarthritis +1 | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00468559 | Apr 2007 → Jun 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00527904 | Mar 2007 → Mar 2009 | gastric ulcer | POZEN | Completed | No outcome recorded |
| Phase 3 | NCT00441727 | Feb 2007 → Aug 2008 | duodenal ulcer, gastric ulcer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00455754 | Feb 2007 → Dec 2009 | lymphocytic gastritis | Technical University Dresden | Unknown | No outcome recorded |
| Phase 3 | NCT00455806 | Jan 2007 → Feb 2008 | Helicobacter pylori infectious disease, chronic gastritis | Technical University Dresden | Unknown | No outcome recorded |
| Phase 3 | NCT00427635 | Oct 2006 → Apr 2009 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00402259 | Aug 2006 → Oct 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00401752 | Mar 2006 → Nov 2008 | gastric ulcer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00251979 | Oct 2005 → Dec 2007 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00206440 | Aug 2005 → Feb 2009 | — | Baylor Breast Care Center | Terminated | No outcome recorded |
| Phase 3 | NCT00243724 | Apr 2005 → Jun 2007 | dyspepsia, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00357682 | Mar 2005 → May 2017 | esophageal cancer, precancerous condition | University of Oxford | Completed | No outcome recorded |
| Phase 3 | NCT00994708 | Dec 2004 → ? | reactive airway disease | Tampere University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00251966 | May 2004 → Sep 2005 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00251901 | May 2004 → Jul 2005 | gastroesophageal reflux disease, intermediate coronary syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241501 | Feb 2004 → Apr 2005 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00079833 | Nov 2003 → Jul 2005 | Zollinger-Ellison syndrome | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00069823 | Sep 2003 → May 2008 | asthma, obstructive lung disease | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| Phase 3 | NCT00164840 | May 2003 → Nov 2008 | gastroesophageal reflux disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00626535 | Mar 2003 → Feb 2004 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00251992 | Dec 2002 → Jan 2005 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00251914 | Dec 2002 → Jan 2005 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00365313 | Aug 2002 → Jun 2005 | arthritic joint disease, ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00251927 | Oct 2001 → Apr 2009 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02670642 | Aug 2001 → Nov 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241553 | Apr 2001 → Feb 2003 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00629512 | Mar 2001 → Dec 2002 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241514 | Feb 2001 → Feb 2003 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00629928 | Feb 2001 → Mar 2003 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00633412 | Feb 2001 → Mar 2003 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00633672 | Feb 2001 → Oct 2003 | active peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241540 | Jan 2001 → Aug 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00241527 | Dec 2000 → Sep 2002 | digestive system disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 492 trials | ||||||
| Phase 4 | NCT07624422 | Nov 2026 → Dec 2027 expected | Helicobacter pylori infectious disease, gastritis, peptic ulcer disease | Damascus Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07611162 | May 2026 → May 2030 expected | gastroesophageal reflux disease | University of Mons | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06283381 | Feb 2024 → Jan 2025 | obesity disorder | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT05624229 | Oct 2023 → Dec 2025 overdue | esophageal varices with bleeding | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06088316 | Feb 2023 → Feb 2024 | Helicobacter pylori infectious disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 4 | NCT05726734 | Feb 2023 → Feb 2025 | Helicobacter pylori infectious disease | Shanghai East Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05664685 | Oct 2022 → Oct 2023 | Helicobacter pylori infectious disease | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT06687499 | Aug 2022 → Dec 2023 | Helicobacter pylori infectious disease | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT06687473 | Jan 2022 → Mar 2023 | Helicobacter pylori infectious disease | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04918017 | Nov 2021 → Dec 2023 | dyspepsia | University of Malaya | Unknown | No outcome recorded |
| Phase 4 | NCT06359015 | Feb 2021 → May 2025 | severe pre-eclampsia | Christiana Care Health Services | Terminated | No outcome recorded |
| Phase 4 | NCT04432233 | Jun 2020 → Apr 2021 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03726099 | Mar 2019 → Apr 2020 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03928470 | Jan → Dec 2019 | gastroesophageal reflux disease | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 4 | NCT03658733 | Dec 2018 → Aug 2019 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT03708848 | Dec 2018 → Sep 2019 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03730766 | Aug → Nov 2018 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03413020 | Jan → Jul 2018 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03555526 | Dec 2017 → Sep 2021 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03208426 | Oct 2017 → Dec 2019 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03092193 | Mar → Oct 2017 | Amobarbital, deficient N-hydroxylation of | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT02935010 | Feb 2017 → Mar 2018 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02933229 | Oct 2016 → Oct 2031 expected | Helicobacter pylori infectious disease, gastric intestinal metaplasia | Shandong University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02711176 | Sep 2016 → Mar 2017 | Helicobacter pylori infectious disease | Zahra Vahdat Shariatpanahi | Completed | No outcome recorded |
| Phase 4 | NCT02794844 | Jul 2016 → Jan 2017 | gastroesophageal reflux disease | Nemours Children's Clinic | Completed | No outcome recorded |
| Phase 4 | NCT03333603 | May 2016 → Jan 2017 | schizophrenia | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02800330 | May 2016 → Feb 2018 | colorectal neoplasm, gastrointestinal stromal tumor | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02624544 | Jan 2016 | psoriasis | EMS | Withdrawn | No outcome recorded |
| Phase 4 | NCT02708355 | Jan → Apr 2016 | dyspepsia | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT03156855 | Sep 2015 → Dec 2018 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02552641 | Sep 2015 → Feb 2016 | Helicobacter pylori infectious disease | EMS | Withdrawn | No outcome recorded |
| Phase 4 | NCT02456012 | Apr 2015 → Dec 2020 | peptic ulcer disease | Hsiu-Chi Cheng | Completed | No outcome recorded |
| Phase 4 | NCT02296021 | Nov 2014 → Sep 2015 | dyspepsia, gastritis, peptic ulcer disease | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT02494856 | Oct 2014 → Dec 2015 | impacted teeth, multiple | Giovana Maria Weckwerth | Completed | No outcome recorded |
| Phase 4 | NCT02134405 | Aug 2014 → Jun 2016 | dyspepsia | University of Malaya | Unknown | No outcome recorded |
| Phase 4 | NCT03128736 | Apr 2014 → Feb 2016 | gastroesophageal reflux disease | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02635191 | Mar 2014 → Mar 2016 | Helicobacter pylori infectious disease | Beijing Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02045251 | Jun 2013 → Jul 2016 | — | American University of Beirut Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02197143 | Mar 2013 → Jul 2014 | dyspepsia | Pamukkale University | Completed | No outcome recorded |
| Phase 4 | NCT02047994 | Mar 2013 → Dec 2033 expected | Helicobacter pylori infectious disease, chronic atrophic gastritis, gastric cancer | International Agency for Research on Cancer | Recruiting | No outcome recorded |
| Phase 4 | NCT02703896 | Jan 2012 | lung disorder | King Saud University | Completed | No outcome recorded |
| Phase 4 | NCT01349413 | Aug 2011 → Dec 2017 | dyspepsia, gastroesophageal reflux disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT01275937 | Aug 2011 → Dec 2013 | active peptic ulcer disease | Taipei Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01397084 | Aug 2011 → Jan 2012 | gastroesophageal reflux disease, peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01249651 | Nov 2010 → Jun 2011 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01887249 | May 2010 → Jul 2013 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00951431 | Dec 2009 → Dec 2015 | dyspepsia | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT00930670 | Jun 2009 → Dec 2011 | coronary artery disorder | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Completed | No outcome recorded |
| Phase 4 | NCT01023360 | May 2008 → Oct 2010 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00641004 | Apr 2008 → Mar 2010 | stomach disorder | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 4 | NCT00660660 | Apr → Jul 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00361985 | Jan 2008 → Jan 2011 | morbid obesity | Weill Medical College of Cornell University | Withdrawn | No outcome recorded |
| Phase 4 | NCT00734097 | Nov 2007 → Oct 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00526006 | Sep 2007 → Mar 2008 | — | Zealand University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00656968 | May 2007 → Jun 2010 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT00444275 | Mar 2007 → Oct 2008 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00443963 | Dec 2006 | dyspepsia | Medstar Health Research Institute | Withdrawn | No outcome recorded |
| Phase 4 | NCT00428701 | Oct → Nov 2006 | gastric ulcer | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00410592 | Oct 2006 → May 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00384592 | Sep 2006 → May 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00363701 | Aug 2006 → Feb 2008 | dyspepsia, gastroesophageal reflux disease, ulcer disease | Glostrup University Hospital, Copenhagen | Unknown | No outcome recorded |
| Phase 4 | NCT00343161 | Aug 2006 → Aug 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00318968 | May 2006 → Nov 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00472550 | Jan → Nov 2006 | dyspepsia, gastroesophageal reflux disease | Heidelberg University | Completed | No outcome recorded |
| Phase 4 | NCT00352261 | Jan 2006 → Apr 2007 | Barrett esophagus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00272701 | Dec 2005 → Feb 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00608712 | Nov 2005 → Aug 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00392002 | Oct 2005 → May 2007 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00242736 | Oct 2005 → Jan 2006 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00230516 | Sep 2005 → Feb 2006 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00471029 | Sep 2005 → Sep 2007 | peptic ulcer disease | Pamela Youde Nethersole Eastern Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00287339 | Sep 2005 → Sep 2008 | gastroesophageal reflux disease | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT00291746 | Sep 2005 → Nov 2006 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00206024 | Nov 2004 → Jul 2005 | dyspepsia | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00228527 | Oct 2004 → Oct 2005 | esophagitis, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00206050 | Sep → Dec 2004 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00206180 | Jun 2004 → Aug 2005 | gastroesophageal reflux disease, peptic esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00625274 | Jun → Nov 2004 | dyspepsia, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00225238 | Dec 2003 → Oct 2007 | — | Thomas Jefferson University | Completed | No outcome recorded |
| Phase 4 | NCT00574925 | Nov 2003 → Oct 2007 | gastroesophageal reflux disease | University of Zurich | Completed | No outcome recorded |
| Phase 4 | NCT00628342 | Apr → Aug 2003 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00318084 | Jan 2003 → ? | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00641602 | Dec 2002 → Aug 2003 | esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00644735 | Dec 2002 → Jan 2004 | esophagitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00625495 | Sep → Nov 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00635414 | Aug → Oct 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00626262 | Jul → Oct 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00637845 | Jun 2002 → Feb 2003 | dyspepsia, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00637988 | Apr 2002 → Jun 2003 | Barrett esophagus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00637559 | Mar 2002 → Apr 2003 | Barrett esophagus | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00628667 | Feb 2002 → Mar 2003 | chronic laryngitis | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00881413 | — | peptic ulcer disease | Lotung Poh-Ai Hospital | Withdrawn | No outcome recorded |
| Phase not applicable31 trials | ||||||
| — | NCT06943794 | Mar 2026 → May 2030 expected | gastric cancer | Fudan University | Not yet recruiting | No outcome recorded |
| — | NCT06953986 | Dec 2025 → Nov 2026 expected | gastroesophageal reflux disease | Asian Institute of Gastroenterology, India | Recruiting | No outcome recorded |
| — | NCT07563491 | Jan → Sep 2025 | gastroesophageal reflux disease | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06250634 | Feb → May 2024 | Helicobacter pylori infectious disease | The Third Xiangya Hospital of Central South University | Completed | No outcome recorded |
| — | NCT05549115 | Sep 2022 → Feb 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Unknown | No outcome recorded |
| — | NCT04991584 | Aug 2021 → Jun 2022 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| — | NCT05097846 | Jun 2021 → Jun 2022 | Helicobacter pylori infectious disease | wang xiaoyan | Unknown | No outcome recorded |
| — | NCT05176821 | Jan 2021 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| — | NCT03717701 | Dec 2018 → Nov 2020 | preeclampsia | Aswan University Hospital | Unknown | No outcome recorded |
| — | NCT04003350 | Dec 2017 → Nov 2018 | osteoarthritis, knee | Rothman Institute Orthopaedics | Completed | No outcome recorded |
| — | NCT03383003 | Mar 2016 → May 2018 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT02730533 | Mar 2016 → Mar 2017 | gastric neoplasm | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| — | NCT02689583 | Mar 2016 → Mar 2017 | gastric ulcer, gastritis | First Affiliated Hospital of Zhejiang University | Unknown | No outcome recorded |
| — | NCT02788591 | Aug 2015 → Jun 2021 | gastroesophageal reflux disease | LCMC Health | Terminated | No outcome recorded |
| — | NCT02359604 | Oct 2014 → Feb 2017 | gastroesophageal reflux disease | Medical University of Graz | Completed | No outcome recorded |
| — | NCT02596620 | Oct 2013 → Oct 2015 | Helicobacter pylori infectious disease | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| — | NCT02884713 | Jun 2013 → Apr 2014 | gastritis | King Faisal Specialist Hospital & Research Center | Completed | No outcome recorded |
| — | NCT01854970 | May 2013 → Jul 2015 | gastroesophageal reflux disease | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT02112812 | Dec 2012 → Mar 2013 | — | National University of Malaysia | Completed | No outcome recorded |
| — | NCT04329000 | Feb 2010 → Feb 2019 | Barrett esophagus, gastroesophageal reflux disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01139645 | Oct 2009 → Jul 2010 | calcium metabolic disease | American University of Beirut Medical Center | Completed | No outcome recorded |
| — | NCT01079884 | Jul 2008 → Mar 2011 | gastroesophageal reflux disease | David A. Johnson, MD | Completed | No outcome recorded |
| — | NCT00604942 | Nov 2007 → Oct 2010 | achalasia, gastroesophageal reflux disease | Guy's and St Thomas' NHS Foundation Trust | Terminated | No outcome recorded |
| — | NCT01547559 | Jun 2007 → Nov 2014 | drug allergy | Sun Yat-sen University | Unknown | No outcome recorded |
| — | NCT00520949 | Oct 2006 → Jun 2008 | — | Aga Khan University | Completed | No outcome recorded |
| — | NCT00546065 | Aug 2006 → Sep 2010 | Barrett esophagus | HSK Wiesbaden | Terminated | No outcome recorded |
| — | NCT00786695 | May 2006 → Dec 2009 | gastroesophageal reflux disease | National University Hospital, Singapore | Completed | No outcome recorded |
| — | NCT00745849 | Jun 2005 → Mar 2008 | vasomotor rhinitis | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| — | NCT00222079 | Nov 2004 → Oct 2007 | gastroesophageal reflux disease | Douglas Trask | Terminated | No outcome recorded |
| — | NCT00162877 | Jun 2004 → Apr 2005 | active peptic ulcer disease, gastritis | National Taiwan University Hospital | Unknown | No outcome recorded |
| — | NCT00516971 | Jan 2003 → Dec 2008 | gastroesophageal reflux disease | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 203 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05100446 Comparator | May → Dec 2021 | Helicobacter pylori infectious disease, gastric cancer, gastritis | Unidade Local de Saúde do Alto Ave, EPE | Unknown | No outcome recorded |
| Phase 123 trials | ||||||
| Phase 1 | NCT06561542 Comparator | Aug 2024 → Nov 2025 overdue | — | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT05586464 Comparator | Nov 2022 → Sep 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT06181084 Background | Oct 2021 → Apr 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT05051566 Background | Sep 2021 → Apr 2022 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT04753437 Comparator | Apr → Sep 2021 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03985319 Comparator | Jul 2019 → Feb 2020 | gastroesophageal reflux disease | Yooyoung Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03530228 Comparator | May → Aug 2018 | — | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 1 | NCT02757144 Comparator | Mar 2016 → Feb 2017 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT01921647 Comparator | Jul → Nov 2013 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT01448031 Background | Nov 2011 → Apr 2012 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01473173 Comparator | Nov 2011 → Aug 2012 | — | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 1 | NCT02680119 Comparator | May 2011 | — | Torrent Pharmaceuticals Limited | Completed | No outcome recorded |
| Phase 1 | NCT01216293 Comparator | Nov 2010 → Aug 2014 | bone disorder | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT01199328 Comparator | Sep → Nov 2010 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT01153659 Comparator | Jul → Aug 2010 | — | Eisai Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01015729 Comparator | Nov 2009 → Mar 2010 | peptic ulcer disease | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT01007019 Comparator | Nov 2009 → Mar 2011 | — | Yuhan Corporation | Completed | No outcome recorded |
| Phase 1 | NCT00998075 Comparator | Sep → Dec 2009 | peptic ulcer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00889850 Comparator | Apr → Jun 2009 | — | Mepha Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01142128 Comparator | Feb 2009 → Dec 2011 | chronic pancreatitis | University of Florida | Terminated | No outcome recorded |
| Phase 1 | NCT00749385 Comparator | Aug → Oct 2008 | arthritic joint disease | POZEN | Completed | No outcome recorded |
| Phase 1 | NCT00444236 Comparator | Apr 2007 → Sep 2009 | exercise-induced bronchoconstriction, gastroesophageal reflux disease | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT00325715 Comparator | Apr → Aug 2006 | peptic ulcer disease | Allergan | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06823791 Background | Aug 2022 → Jul 2024 | Helicobacter pylori infectious disease | Liaocheng People's Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT05287633 Comparator | Jan → Dec 2020 | dyspepsia | University of Monastir | Completed | No outcome recorded |
| Phase 1/2 | NCT01129713 Comparator | May 2010 → May 2015 | dyspepsia, gastroesophageal reflux disease | Effexus Pharmaceutical | Unknown | No outcome recorded |
| Phase 1/2 | NCT00564330 Comparator | Nov 2007 → Apr 2008 | tooth erosion, non-bacterial | Brain-Gut Research Group | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT07144657 Background | Sep 2025 → Dec 2029 expected | gastric mucosa-associated lymphoid tissue lymphoma | National Taiwan University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06903585 Comparator | Apr 2025 → Apr 2029 expected | bone pain, periodic, metastatic carcinoma in the bone | American University of Beirut Medical Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06783257 Comparator | Feb 2025 → Feb 2027 expected | active peptic ulcer disease | Shandong New Time Pharmaceutical Co., LTD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT04282954 Comparator | Nov 2019 → Oct 2020 | gastroesophageal reflux disease | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03625050 Comparator | Nov 2018 → Dec 2020 | — | Gachon University Gil Oriental Medical Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03184324 Comparator | Aug 2017 → Apr 2018 | gastroesophageal reflux disease | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 2 | NCT02637557 Background | Mar 2016 → Apr 2017 | gastroesophageal reflux disease | Ironwood Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02307305 Background | Aug 2014 → Dec 2016 | neuropathy, painful | Hanyang University Seoul Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02090738 Comparator | Mar → Dec 2014 | Helicobacter pylori infectious disease | Yonsei University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02028663 Comparator | May 2013 → May 2014 | esophagitis, gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01750437 Comparator | Jan → Oct 2013 | gastroesophageal reflux disease | Yuhan Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01538849 Comparator | Dec 2012 → Nov 2013 | peptic esophagitis | Yuhan Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01107938 Comparator | May → Jun 2010 | gastroesophageal reflux disease | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT01059383 Comparator | Dec 2009 → Jun 2011 | gastroesophageal reflux disease | Vecta Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00978016 Background | Sep 2009 → Dec 2010 | gastroesophageal reflux disease | XenoPort, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01138969 Comparator | Aug 2008 → Dec 2012 | peptic ulcer disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 2 | NCT01983774 Comparator | Feb 2008 → Aug 2011 | cystic fibrosis | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT00730665 Comparator | Jan → Oct 2008 | gastroesophageal reflux disease | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT00474903 Background | Apr 2007 → Mar 2011 | Barrett esophagus, esophageal cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00303264 Background | May 2006 → Aug 2007 | dyspepsia | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00123656 Comparator | Aug 2004 → Dec 2006 | esophagitis | University of Utah | Completed | No outcome recorded |
| Phase 2 | NCT00164788 Comparator | Jul 2004 → Jan 2011 | — | Chinese University of Hong Kong | Terminated | No outcome recorded |
| Phase 2 | NCT00222131 Comparator | Oct 2003 → Jan 2008 | dyspepsia | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06591494 Comparator | Sep 2024 → Sep 2025 overdue | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT00728481 Comparator | May 2008 → Dec 2010 | eosinophilic esophagitis, gastroesophageal reflux disease | Mayo Clinic | Completed | No outcome recorded |
| Phase 328 trials | ||||||
| Phase 3 | NCT07606833 Comparator | Jun 2026 → Feb 2027 expected | Helicobacter pylori infectious disease | Xuanzhu Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06760065 Comparator | Jan 2025 → Dec 2027 expected | Helicobacter pylori infectious disease | Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07326904 Comparator | Sep → Oct 2024 | gastroesophageal reflux disease | Indonesia University | Completed | No outcome recorded |
| Phase 3 | NCT06162949 Comparator | Jan → Aug 2024 | — | Alexandria University | Completed | No outcome recorded |
| Phase 3 | NCT05267613 Comparator | Jul 2022 → Aug 2026 overdue | esophagitis | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05443984 Comparator | Jan 2022 → Jan 2023 | esophagitis | Onconic Therapeutics Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05841394 Comparator | Jul 2021 → Apr 2022 | peptic ulcer disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT04652284 Comparator | May 2021 → May 2023 | Helicobacter pylori infectious disease, bacterial gastritis, primary bacterial infectious disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04198363 Comparator | Apr 2020 → Nov 2021 | Helicobacter pylori infectious disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT03736369 Comparator | Dec 2018 → Aug 2019 | esophagitis | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 3 | NCT03615677 Comparator | Oct 2018 → Oct 2019 | esophagitis | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT03006874 Comparator | May 2016 → Mar 2017 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT01670552 Comparator | Feb → Oct 2016 | dyspepsia | EMS | Completed | No outcome recorded |
| Phase 3 | NCT02456935 Comparator | May 2015 → Jul 2016 | esophagitis | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 3 | NCT03142620 Comparator | Mar 2015 → Dec 2017 | Helicobacter pylori infectious disease | Chinese University of Hong Kong | Unknown | No outcome recorded |
| Phase 3 | NCT01579539 Background | Jun 2013 → May 2017 | dry eye syndrome, thyrotoxic exophthalmos | Medical University of Vienna | Completed | No outcome recorded |
| Phase 3 | NCT01873079 Comparator | Apr 2013 → Mar 2016 | hemorrhagic disease | The University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT02767479 Comparator | Jul 2012 → Apr 2016 | Helicobacter pylori infectious disease | Hamamatsu University | Completed | No outcome recorded |
| Phase 3 | NCT02860624 Comparator | Dec 2011 → Apr 2013 | gastroesophageal reflux disease | Livzon Pharmaceutical Group Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01132638 Comparator | Aug 2011 → Jun 2012 | gastroesophageal reflux disease | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00857597 Comparator | Mar 2009 → Dec 2011 | gastroesophageal reflux disease | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 3 | NCT00699426 Comparator | Jun 2008 → Jun 2009 | type 2 diabetes mellitus | Lise Tarnow | Completed | No outcome recorded |
| Phase 3 | NCT00658528 Comparator | Feb 2008 → Sep 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00658632 Comparator | Feb 2008 → Apr 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00658775 Comparator | Feb 2008 → Sep 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01142245 Comparator | Jan 2008 → Dec 2013 | hemorrhagic disease, peptic ulcer disease | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 3 | NCT00542347 Comparator | Sep 2007 → Apr 2017 | achlorhydria | Queen's University | Terminated | No outcome recorded |
| Phase 3 | NCT01471925 Comparator | — | gastroesophageal reflux disease | Eurofarma Laboratorios S.A. | Withdrawn | No outcome recorded |
| Phase 484 trials | ||||||
| Phase 4 | NCT07590648 Background | Jun 2026 → Jul 2028 expected | bacterial infectious disease, childhood malignant neoplasm, hematopoietic and lymphoid cell neoplasm, neutropenia | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07312370 Background | Apr → Dec 2026 expected | active peptic ulcer disease, gastric carcinoma, gastric ulcer | LanZhou University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07537634 Comparator | Apr → Aug 2026 overdue | Helicobacter pylori infectious disease, dyspepsia, peptic ulcer disease | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Recruiting | No outcome recorded |
| Phase 4 | NCT07139366 Background | Oct 2025 → Sep 2026 expected | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Yongquan Shi | Recruiting | No outcome recorded |
| Phase 4 | NCT07146594 Comparator | Aug 2025 → May 2026 overdue | Helicobacter pylori infectious disease, active peptic ulcer disease | Athens Medical Center | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07268820 Comparator | Jul 2025 → May 2026 overdue | gastroesophageal reflux disease | Incheon St.Mary's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06959368 Comparator | Mar 2025 → Mar 2026 overdue | Helicobacter pylori infectious disease | Asian Institute of Gastroenterology, India | Recruiting | No outcome recorded |
| Phase 4 | NCT06720610 Comparator | Dec 2024 → Apr 2025 overdue | esophagitis | Indonesia University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06523764 Comparator | Nov 2024 → Aug 2025 overdue | chronic gastritis | Xijing Hospital of Digestive Diseases | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06514274 Comparator | Sep 2024 → Apr 2025 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT06526455 Comparator | Aug 2024 → Jun 2029 expected | gastric ulcer | Shicai Ye | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06509139 Comparator | Jul 2024 → Jul 2032 expected | Helicobacter pylori infectious disease | National Cheng-Kung University Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06318104 Comparator | Apr → Nov 2024 | Helicobacter pylori infectious disease | Hospital General de México Dr. Eduardo Liceaga | Unknown | No outcome recorded |
| Phase 4 | NCT06065267 Comparator | Jan 2024 → Dec 2026 expected | Helicobacter pylori infectious disease | Damascus Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06603688 Background | Nov 2023 → Nov 2024 | Helicobacter pylori infectious disease, chronic gastritis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 4 | NCT05647278 Comparator | Nov 2023 → Sep 2025 | Helicobacter pylori infectious disease | Zhang Xiaofeng,MD | Completed | No outcome recorded |
| Phase 4 | NCT05874570 Background | Jun 2023 → Oct 2025 overdue | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 4 | NCT06168084 Comparator | Jun 2023 → May 2024 | stomach disorder | Yongquan Shi | Completed | No outcome recorded |
| Phase 4 | NCT05582174 Comparator | May 2023 → Jan 2028 expected | active peptic ulcer disease | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 4 | NCT05701540 Comparator | Mar 2023 → Dec 2024 | gastroesophageal reflux disease | HK inno.N Corporation | Unknown | No outcome recorded |
| Phase 4 | NCT05802888 Background | Mar 2023 → Jun 2024 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05742568 Comparator | Dec 2022 → Dec 2023 | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT05431075 Background | Jul 2022 → Feb 2024 | Helicobacter pylori infectious disease | Shandong University | Completed | No outcome recorded |
| Phase 4 | NCT05432115 Background | Jun 2022 → Aug 2023 | Helicobacter pylori infectious disease | Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT05590286 Comparator | Jun 2022 → Dec 2024 | Helicobacter pylori infectious disease, proton-pump inhibitor-responsive esophageal eosinophilia | First People's Hospital of Hangzhou | Unknown | No outcome recorded |
| Phase 4 | NCT05196945 Comparator | Mar → Dec 2022 | — | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT05250050 Background | Mar → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04558502 Background | Jan → Jun 2022 | — | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04907747 Comparator | May 2021 → Apr 2022 | Helicobacter pylori infectious disease | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT04448028 Comparator | Apr 2021 → Feb 2028 expected | cirrhosis of liver | University Medical Center Hamburg-Eppendorf | Recruiting | No outcome recorded |
| Phase 4 | NCT04678492 Comparator | Dec 2020 → Dec 2021 | Helicobacter pylori infectious disease, dyspepsia, gastric cancer, gastritis +1 | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04660123 Background | Dec 2020 → Dec 2021 | Helicobacter pylori infectious disease, gastric cancer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04626193 Background | Oct 2020 → Dec 2023 | Helicobacter pylori infectious disease | Damascus Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04531059 Background | Oct 2020 → Dec 2022 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04309916 Comparator | May 2020 → Nov 2021 | gastroesophageal reflux disease | HK inno.N Corporation | Completed | No outcome recorded |
| Phase 4 | NCT04527055 Comparator | May 2020 → Jul 2028 expected | Helicobacter pylori infectious disease, immune dysregulation, neurodevelopmental defects, and colitis | National Cheng-Kung University Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT05237115 Background | May → Dec 2020 | dyspepsia, gastritis, peptic ulcer disease | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT04445948 Comparator | Nov 2019 → Jun 2020 | Helicobacter pylori infectious disease | Alexandria University | Completed | No outcome recorded |
| Phase 4 | NCT04090021 Background | Sep 2019 → Feb 2020 | Helicobacter pylori infectious disease | Konstantopoulio-Patission General Hospital of Nea Ionia | Unknown | No outcome recorded |
| Phase 4 | NCT04024527 Background | Jul 2019 → Apr 2021 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT04034641 Background | Jun 2019 → Dec 2020 | active peptic ulcer disease | Hangzhou Grand Biologic Pharmaceutical, Inc. | Unknown | No outcome recorded |
| Phase 4 | NCT03908619 Comparator | Apr 2019 → Mar 2021 | Helicobacter pylori infectious disease | Changi General Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT04769583 Comparator | Feb 2019 → Feb 2020 | bacterial gastritis | mohamed bouchoucha | Completed | No outcome recorded |
| Phase 4 | NCT04348786 Background | Feb 2019 → Aug 2020 | Helicobacter pylori infectious disease | Damascus Hospital | Completed | No outcome recorded |
| Phase 4 | NCT05635942 Background | Jan 2019 → Aug 2022 | Helicobacter pylori infectious disease | Les Laboratoires des Médicaments Stériles | Completed | No outcome recorded |
| Phase 4 | NCT03722433 Background | Aug 2018 → Jul 2019 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03609892 Comparator | Aug 2018 → Aug 2019 | Helicobacter pylori infectious disease, chronic gastritis, gastric cancer, gastric ulcer | Xijing Hospital of Digestive Diseases | Completed | No outcome recorded |
| Phase 4 | NCT03094416 Background | Jul 2018 → Jun 2020 | postsurgical hypothyroidism | IBSA Institut Biochimique SA | Completed | No outcome recorded |
| Phase 4 | NCT03557437 Background | May 2018 → Jun 2019 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03592069 Comparator | Feb 2018 → Oct 2020 | Helicobacter pylori infectious disease | Alexandra Hospital, Athens, Greece | Completed | No outcome recorded |
| Phase 4 | NCT03405584 Background | Jan → Nov 2018 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT03021590 Background | Jun 2017 → Dec 2021 | Helicobacter pylori infectious disease | Damascus Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02959255 Comparator | Jan → Dec 2017 | Helicobacter pylori infectious disease | Elpen Pharmaceutical Co. Inc. | Completed | No outcome recorded |
| Phase 4 | NCT02530879 Comparator | May 2016 → Aug 2017 | upper respiratory tract disorder | Temple University | Withdrawn | No outcome recorded |
| Phase 4 | NCT02732249 Background | Apr 2016 → Sep 2017 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT02894268 Background | Feb 2016 → Oct 2018 | Helicobacter pylori infectious disease | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03220542 Background | Jan 2016 → Dec 2018 | Helicobacter pylori infectious disease | Kyunghee University Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02553083 Comparator | Oct 2015 → Sep 2020 | Helicobacter pylori infectious disease | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT02476097 Comparator | Jun 2015 → Dec 2023 | stomach disorder | Victoria Rollason | Unknown | No outcome recorded |
| Phase 4 | NCT02277886 Background | Nov 2014 → Jun 2016 | dyspepsia, gastroesophageal reflux disease, sleep disorder | Chang Gung Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02205489 Background | Oct 2014 → Apr 2016 | relapsing-remitting multiple sclerosis | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 4 | NCT01725906 Background | Nov 2012 → May 2017 | — | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01667575 Background | Aug 2012 → May 2013 | Helicobacter pylori infectious disease, dyspepsia, peptic ulcer disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT01591083 Comparator | Aug 2011 → Jul 2014 | active peptic ulcer disease | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01874535 Comparator | Jun 2010 → Jun 2016 | esophagitis | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01123031 Comparator | Apr 2010 → Mar 2012 | active peptic ulcer disease | Changhua Christian Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT01119768 Comparator | Apr 2010 → Jun 2011 | chronic gastritis, gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT01822600 Background | Jan 2010 → Aug 2011 | active peptic ulcer disease | National Cheng-Kung University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01062516 Comparator | Jan → Sep 2010 | acute coronary syndrome, acute myocardial infarction | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00978159 Comparator | Sep 2009 → Dec 2013 | dyspepsia | Ruttonjee Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00885417 Background | Apr 2009 → Dec 2010 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00825630 Comparator | Nov 2008 → Nov 2009 | Helicobacter pylori infectious disease | Meridian Bioscience, Inc. | Completed | No outcome recorded |
| Phase 4 | NCT01085786 Comparator | Aug 2008 → May 2010 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| Phase 4 | NCT00683111 Comparator | Jul 2008 → Dec 2011 | acute coronary syndrome, acute myocardial infarction | Ruttonjee Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00633035 Comparator | Sep 2007 → Mar 2010 | ulcer disease | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00464308 Comparator | Nov 2006 → May 2008 | gastroesophageal reflux disease | Janssen-Cilag Pty Ltd | Completed | No outcome recorded |
| Phase 4 | NCT00719160 Comparator | Jan 2005 → May 2008 | osteoporosis | Yale University | Completed | No outcome recorded |
| Phase 4 | NCT00590928 Comparator | Jul 2004 → Jun 2006 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT00155389 Comparator | Jan 2004 → Dec 2015 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00120315 Comparator | Dec 2003 → Mar 2007 | dyspepsia | Odense University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01792700 Comparator | Jan 2003 → Dec 2010 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00629564 Comparator | Sep → Oct 2002 | gastroesophageal reflux disease | AstraZeneca | Completed | No outcome recorded |
| Phase 4 | NCT00184522 Comparator | Aug 2002 → Nov 2004 | gastroesophageal reflux disease | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 4 | NCT00473980 Background | Dec 1998 → May 2007 | colorectal cancer | Göteborg University | Completed | No outcome recorded |
| Phase not applicable38 trials | ||||||
| — | NCT07010744 Background | Jul 2025 → Jun 2026 overdue | dyspepsia | Akil Al Islam | Enrolling by invitation | No outcome recorded |
| — | NCT06955520 Comparator | Apr 2025 → Dec 2027 expected | gastroesophageal reflux disease | Asian Institute of Gastroenterology, India | Recruiting | No outcome recorded |
| — | NCT06810492 Background | Apr → Dec 2025 overdue | female breast carcinoma | Hongmei Zheng, PhD | Not yet recruiting | No outcome recorded |
| — | NCT06851468 Comparator | Mar → Nov 2025 | Helicobacter pylori infectious disease | Key Laboratory for Gastrointestinal Diseases of Gansu Province | Completed | No outcome recorded |
| — | NCT07260006 Background | Oct 2024 → May 2026 overdue | Helicobacter pylori infectious disease, peptic ulcer disease | Can Tho University of Medicine and Pharmacy | Recruiting | No outcome recorded |
| — | NCT07337135 Background | Oct 2023 → Apr 2024 | morbid obesity | Hospital dos Lusíadas | Completed | No outcome recorded |
| — | NCT05870683 Comparator | May → Oct 2023 | Helicobacter pylori infectious disease | Yanqing Li | Unknown | No outcome recorded |
| — | NCT05449028 Background | May 2022 → Dec 2023 | Helicobacter pylori infectious disease | Unidade Local de Saúde de Coimbra, EPE | Unknown | No outcome recorded |
| — | NCT05189444 Comparator | Mar → Dec 2022 | Helicobacter pylori infectious disease | Huazhong University of Science and Technology | Unknown | No outcome recorded |
| — | NCT04879992 Background | May 2021 → Oct 2022 | Helicobacter pylori infectious disease | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| — | NCT06382493 Comparator | Feb 2021 → Dec 2026 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT04720781 Comparator | Jan 2021 → Dec 2024 | gastroesophageal reflux disease | Showa Inan General Hospital | Completed | No outcome recorded |
| — | NCT04359966 Comparator | May 2020 → May 2023 | Helicobacter pylori infectious disease | Slovenian Society for Gastroenterology and Hepatology | Unknown | No outcome recorded |
| — | NCT05850117 Comparator | Feb 2020 → Dec 2024 | — | Kaohsiung Medical University | Unknown | No outcome recorded |
| — | NCT04006340 Background | Jan → Aug 2019 | Helicobacter pylori infectious disease | Seoul National University Hospital | Unknown | No outcome recorded |
| — | NCT03724838 Comparator | Dec 2018 → Nov 2021 | preeclampsia | Aswan University Hospital | Unknown | No outcome recorded |
| — | NCT03688828 Background | Nov 2018 → Jun 2020 | Helicobacter pylori infectious disease | Huazhong University of Science and Technology | Completed | No outcome recorded |
| — | NCT03779087 Background | Jul 2018 → Jun 2020 | Helicobacter pylori infectious disease | Ping-I (William) Hsu, M.D. | Completed | No outcome recorded |
| — | NCT03572777 Background | Apr 2018 → Oct 2019 | Helicobacter pylori infectious disease | Antonio Mestrovic | Completed | No outcome recorded |
| — | NCT03040817 Comparator | Sep 2017 → Aug 2019 | — | Zhongda Hospital | Unknown | No outcome recorded |
| — | NCT02984930 Comparator | Dec 2016 → Jul 2018 | gastroesophageal reflux disease | Gangnam Severance Hospital | Unknown | No outcome recorded |
| — | NCT02894892 Comparator | Nov 2016 → Oct 2017 | Helicobacter pylori infectious disease | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT02840929 Background | Jul 2016 → Sep 2017 | active peptic ulcer disease, gastric ulcer | The University of Hong Kong | Terminated | No outcome recorded |
| — | NCT03812419 Comparator | Jan → Dec 2016 | — | Future University in Egypt | Completed | No outcome recorded |
| — | NCT03598738 Comparator | Dec 2015 → Dec 2017 | type 2 diabetes mellitus | Baskent University Ankara Hospital | Completed | No outcome recorded |
| — | NCT02978157 Comparator | Feb 2015 → Sep 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT02373280 Comparator | Aug 2014 → Apr 2027 expected | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Recruiting | No outcome recorded |
| — | NCT02071316 Comparator | Apr 2014 → Apr 2015 | — | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| — | NCT02434978 Comparator | Jan 2014 → Sep 2017 | active peptic ulcer disease | Odense University Hospital | Unknown | No outcome recorded |
| — | NCT02547012 Background | Nov 2013 → Jul 2017 | Helicobacter pylori infectious disease | Kaohsiung Veterans General Hospital. | Completed | No outcome recorded |
| — | NCT01643785 Background | Jun 2012 → Jun 2013 | Helicobacter pylori infectious disease | Chuncheon Sacred Heart Hospital | Terminated | No outcome recorded |
| — | NCT01760824 Background | May 2011 → Oct 2012 | Helicobacter pylori infectious disease | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT02349685 Background | Jan 2010 → Jun 2014 | Helicobacter pylori infectious disease | Seoul National University Bundang Hospital | Completed | No outcome recorded |
| — | NCT02081404 Comparator | Mar 2009 → Jan 2020 | gastroesophageal reflux disease | Midwest Biomedical Research Foundation | Completed | No outcome recorded |
| — | NCT01306786 Comparator | Nov 2008 → Oct 2010 | Helicobacter pylori infectious disease | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01710800 Comparator | Sep 2008 → Sep 2012 | gastroesophageal reflux disease | Walter Reed National Military Medical Center | Completed | No outcome recorded |
| — | NCT00895817 Comparator | Apr 2008 → Oct 2010 | eosinophilic esophagitis | Walter Reed Army Medical Center | Completed | No outcome recorded |
| — | NCT00170001 Comparator | Apr 2005 → Aug 2006 | gastroesophageal reflux disease | Mayo Clinic | Completed | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-04-18 | Daiichi Sankyo | AstraZeneca and Daiichi Sankyo Launch Proton Pump Inhibitor Nexium® 10 mg and 20 mg Granules for Suspension, Sachet, in Japan daiichisankyo.com ↗ |
| 2018-01-19 | Daiichi Sankyo | Nexium® 10 mg and 20 mg Capsules received additional approval of paediatric dosage and administration, and marketing approval of Nexium® 10 mg and 20 mg Granules for Suspension, Sachet in Japan daiichisankyo.com ↗ |
| 2015-01-26 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives FDA Approval for First Generic Nexium® Delayed-Release Capsules in the United States tevapharm.com ↗ |
| 2012-08-13 | Pfizer | Pfizer And Astrazeneca Enter Into Agreement For Over-The-Counter Nexium pfizer.com ↗ |
| 2012-06-22 | Daiichi Sankyo | NEXIUM receives approval in Japan for prevention of recurrence of gastric ulcer and duodenal ulcer in patients treated with aspirin at low doses daiichisankyo.com ↗ |
| 2011-10-24 | Daiichi Sankyo | Application Submitted in Japan for Additional Indication for NEXIUM® 10mg and 20mg Capsules daiichisankyo.com ↗ |
| 2011-09-15 | Daiichi Sankyo | Daiichi Sankyo and AstraZeneca Launch NEXIUM(R) 10mg and 20mg Capsules in Japan daiichisankyo.com ↗ |
| 2011-07-01 | Daiichi Sankyo | NEXIUM receives first regulatory approval in Japan for the treatment of acid-related disease daiichisankyo.com ↗ |
| 2010-10-29 | Daiichi Sankyo | AstraZeneca and Daiichi Sankyo Announce Co-Promotion Agreement for Esomeprazole Proton Pump Inhibitor in Japan daiichisankyo.com ↗ |
| 2010-01-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Settlement Agreements With AstraZeneca Regarding Generic Prilosec® and Nexium® tevapharm.com ↗ |
| 2005-04-29 | Vertex Pharmaceuticals Incorporated | New Pharmacokinetic Data On Taking Lexiva Simultaneously With Nexium vrtx.com ↗ |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 480 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | esomeprazole | “Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg...” PMID 16961802 ↗ Oct 2006453“A is amoxicillin (1000 mg thrice daily), B is colloidal bismuth subcitrate (120 mg thrice daily), M is metronidazole (500 mg thrice daily), P is a proton pump inhibitor, i.e.,...” NCT06687473 ↗ “This is a multicenter, randomized, double blind, double-simulated, parallel control of positive drug phase III clinical study to evaluate the efficacy and safety of Anaprazole...” NCT07606833 ↗ “Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40...” NCT00978016 ↗ “Treatment for H. pylori Patients with positive Urea Breath Test (positive for H. pylori infection) will be started on eradication therapy of H. pylori (oral esomeprazole 40mg...” NCT02112812 ↗ “An Open-label, Randomized, Single-center, 2-way Cross-over Interaction Study, Evaluating the Effect of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg on the Pharmacodynamics and...” NCT01210339 ↗ “Fourteen-day esomeprazole, tripotassium dicitrate bismuthate, metronidazole and tetracycline (EBMT) therapy or esomeprazole, moxifloxacin and amoxicillin (MEA) therapy was...” PMID 26452405 ↗ Oct 2015 “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “including a proton pump inhibitor (Esomeprazole 20 mg), Bismuth Potassium Citrate 220 mg, and two antibiotics selected based on susceptibility testing (e.g., Amoxicillin,...” NCT06760065 ↗ “A Phase III, Randomized, Open-label, Superiority Study Comparing the Incremental Product Esomeprazole Associated With Sodium Bicarbonate Made by Eurofarma and Nexium® in the...” NCT01471925 ↗ “Study participants will receive fixed dose of esomeprazole administered orally in a pre-specified sequence during the Treatment Period of Part A. This is a non-investigational...” NCT05845645 ↗ “A modified and optimized bismuth quadruple therapy that comprises: 40 mg of esomeprazole bid, amoxicillin 1g tds, metronidazole 500mg tds and bismuth subcitrate 240mg bid, all...” NCT07146594 ↗ “Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole...” NCT00885417 ↗ “The fixed-dose combination of esomeprazole and magnesium hydroxide showed rapid absorption and quicker gastric acid suppression than enteric-coated esomeprazole with comparable...” PMID 39289057 ↗ Sep 2024 “The intervention group will be treated with Esomeprazole 40 mg every 8 hours, Amoxicillin 1 gr every 8 hours, Metronidazole 500 mg every 8 hours, Bismuth subsalicylate 369 mg...” NCT05664685 ↗ “After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.” NCT01822600 ↗ “Subjects to compare the single dose bioavailability of Torrent's Esomeprazole Mg DR Capsule 1×40 mg and Nexium 40 mg DR Capsule containing Esomeprazole 40 mg of AastraZeneca LP, USA.” NCT02680119 ↗ “YYD601 was developed as a novel dual delayed release (DDR) formulation of esomeprazole to prolong the plasma esomeprazole concentration and extend the duration of acid suppression.” PMID 35281316 ↗ Mar 2022 “esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks” NCT01547559 ↗ “An Open-Label, Randomized, Four-Way Crossover Study to Evaluate the Effect of Food on the Bioavailability of Naproxen and Esomeprazole From a PN 400 Tablet in Healthy Subjects” NCT00676442 ↗ “D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days” NCT03156855 ↗ “D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days” NCT03148366 ↗ “A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), bismuth subcitrate (or bismuth subsalicylate), amoxicillin, and metronidazole.” NCT07260006 ↗ “esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days” NCT01085786 ↗ “Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.” NCT05267613 ↗ “which received (bismuth subsalicylate 524 mg four times daily, doxycycline 100 mg, tinidazole 500 mg, and esomeprazole 20 mg, each twice per day for 2 weeks)” PMID 34218802 ↗ Jul 2021 “Long-term safety of naproxen and esomeprazole magnesium fixed-dose combination: phase III study in patients at risk for NSAID-associated gastric ulcers.” PMID 21319944 ↗ Feb 2011 “YYD601 is a new dual delayed-release formulation of esomeprazole, developed to enhance plasma exposure and prolong the duration of acid suppression.” PMID 39803609 ↗ Jan 2025 “Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.” NCT02788591 ↗ “To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.” NCT05513625 ↗ “Concomitant for 10 days, including 40 mg of esomeprazole bid, amoxicillin 1g bid, clarithromycin 500mg bid and metronidazole 500mg bid.” NCT03592069 ↗ “10 days tailored therapy including one Proton Pump Inhibitor ( Rabeprazole 0.4-0.5mg/kg.d,bid. or Esomeprazole 0.8-1.0mg/kg.d,bid)” NCT02635191 ↗ “levofloxacin 500 mg daily, tinidazole 500 mg, amoxicillin 1000 mg, and esomeprazole 20 mg each twice per day for two weeks” NCT07624422 ↗ “coadministered enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg (fixed-dose combination)” PMID 22078153 ↗ Nov 2011 “esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days” NCT05549115 ↗ “Arm B, the same chemotherapy preceded by three days esomeprazole (ESOM) 80 mg p.o. bid, beginning on d1 repeated weekly.” PMID 26297142 ↗ Aug 2015 “we examined the effect of esomeprazole on insulin secretion, HbA(1c) and cardiovascular risk factors in type 2 diabetes.” PMID 23011351 ↗ Sep 2012 “esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.” NCT03779087 ↗ “PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).” NCT00594854 ↗ “Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects” NCT00230516 ↗ “Esomeprazole 40mg bid + amoxicillin 1g 12/12h + clarithromycin 500mg 12/12h + metronidazole 500mg 8/8h, for 14 days” NCT05449028 ↗ “EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg) or NexiumⓇ (esomeprazole 20 mg) once daily for 4 weeks” PMID 35730245 ↗ Jun 2022 “esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.” NCT01306786 ↗ “H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.” NCT02933229 ↗ “Standard triple therapy will be based on Esomeprazole 20 mg BD, Clarithromycin 500mg BD and Amoxicillin 1gm BD.” NCT07010744 ↗ “All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.” NCT02434978 ↗ “Triple therapy for H. pylori infection (Esomeprazole, Amoxicillin, and Clarithromycin) for two weeks” NCT05297695 ↗ “PPI(pantoprazole 40mg, lansoprazole 30mg, esomeprazole 40mg, rabeprazole 20mg, omeprazole 20mg)” NCT01643785 ↗ “Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) in HPMC capsule” NCT01964131 ↗ “Esomeprazole 20 mg BID Bismuth pectin 200 mg BID Amoxicillin 1 g BID Clarithromycin 500 mg BID” NCT06591494 ↗ “Standard doses of proton pump inhibitors are esomeprazole 20mg, rabeprazole 10mg (or 20mg).” NCT04660123 ↗ “Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid” NCT05802888 ↗ “the dual delayed-release formulation of 10-mg esomeprazole (HIP2101) are currently limited” PMID 39949051 ↗ Feb 2025 “Tid group: Amoxicillin 1000mg bid+ Tetracycline 500mg tid+ Bismuth + Esomeprazole 40mg bid” NCT05432115 ↗ “For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.” NCT02689583 ↗ “Esomeprazole (Nexium®, AstraZeneca Korea, Co. Ltd., Seoul, Korea) 40 mg, bid, for 7 days” NCT02090738 ↗ “500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9” NCT00599404 ↗ “PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.” NCT01129011 ↗ “PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.” NCT00527787 ↗ “esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 days” NCT04006340 ↗ “omeprazole, esomeprazole, lansoprazole, dexlansoprazole, pantoprazole, rabeprazole” NCT03094416 ↗ “single-tablet naproxen 500 mg/esomeprazole 20 mg (NAP/ESO) given twice daily” PMID 26313454 ↗ Aug 2015 “Use of Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole” NCT07611162 ↗ “The medication used (esomeprazole) in this trial is approved by the FDA” NCT02359604 ↗ “P is a proton pump inhibitor, i.e., esomeprazole (40 mg twice daily)” NCT06687499 ↗ “Either twice daily esomeprazole 40 mg or placebo for 6 months.” NCT00170001 ↗ “esomeprazole (Medis Pharmaceutical Company) 40 mg twice daily” NCT05635942 ↗ “Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5” NCT01153659 ↗ “Drug: JP-1366 A mg or JP-1366 Placebo or Esomeprazole 40 mg” NCT03383042 ↗ “clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week” NCT01023360 ↗ “prophylactic esomeprazole cream (termed "Dermaprazole")” NCT05269160 ↗ “Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid)” NCT05586464 ↗ “1. Omeprazole (or esomeprazole): 20mg, 2 times/day” NCT06943794 ↗ “D1-D7: (esomeprazole + amoxicillin bid) for 7 days” NCT03722433 ↗ “esomeprazole (40 mg daily) from day 1 to day 10” NCT00656968 ↗ “Esomeprazole ('Emanera') 40 mg bid for 14 days” NCT03572777 ↗ “esomeprazole magnesium enteric-coated tablets” NCT04034641 ↗ “* Esomeprazole for stress-ulcer prevention.” NCT07337135 ↗ “Nexium (esomeprazole), 40mg, bid, 14 days” NCT01725906 ↗ “40 mg esomeprazole will be administered” NCT03978143 ↗ “naproxen 375 mg / esomeprazole 20 mg” NCT00692055 ↗ “500mg Naproxen and 20mg esomeprazole” NCT00992381 ↗ “naproxen 500 mg /esomeprazole 20 mg” NCT00665743 ↗ “Esomeprazole 40 mg bid for 10 days” NCT02047994 ↗ “Esomeprazole magnesium Dihydrate.” NCT03967886 ↗ “Esomeprazole 20mg bid for 10 days” NCT01760824 ↗ “esomeprazole: 40 mg x 2 per day” NCT04769583 ↗ “PPI (Esomeprazole 20mg b.i.d)” NCT02045251 ↗ “Esomeprazole 20mg tablets BID” NCT06101420 ↗ “Group E(esomeprazole 20 mg)” NCT02703896 ↗ “Esomeprazole 20 mg Capsule” NCT03021590 ↗ “Esso (esomeprazole)” NCT00520949 ↗ “Drug: Esomeprazole” NCT05624229 ↗ “Drug: Esomeprazole” NCT02757144 ↗ “Oral esomeprazole” NCT04080726 ↗ “Esomeprazole” NCT00857597 ↗ “Esomeprazole” NCT06810492 ↗ |
| Known as | D961H | “This is a phase 3 multicentre, randomised, double-blind, parallel-group, comparative study to evaluate the efficacy of esomeprazole (D961H) 20 mg twice daily and esomeprazole...” NCT01669811 ↗3“The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment” NCT00542789 ↗ “Drug-Drug Interaction Study of Esomeprazole (D961H) Capsule and Loxoprofen Tablet After Repeated Oral Administration in Japanese Males” NCT00676117 ↗ “Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer” NCT00595517 ↗ |
| Known as | Dermaprazole | “prophylactic esomeprazole cream (termed "Dermaprazole")” NCT05269160 ↗ |
| Known as | Emanera | “Esomeprazole ('Emanera') 40 mg bid for 14 days” NCT03572777 ↗ |
| Known as | EPZ | “esomeprazole (EPZ) + bismuth + doxycycline + furazolidone” PMID 37214450 ↗ May 2023 |
| Known as | ESO | “To investigate the effect of esomeprazole (ESO) on the pharmacokinetics of pritelivir (PTV), and to investigate the safety and tolerability of PTV.” NCT05513625 ↗ |
| Known as | ESOM | “Arm B, the same chemotherapy preceded by three days esomeprazole (ESOM) 80 mg p.o. bid, beginning on d1 repeated weekly.” PMID 26297142 ↗ Aug 2015 |
| Known as | esomeprazole magnesium | “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗9“The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and...” NCT00206180 ↗ “esomeprazole magnesium 20 mg bid +colloidal bismuth pectin 200mg bid + amoxicillin 1000 mg bid + furazolidone 100 mg bid, for 14 days.” NCT06823791 ↗ “fixed-dose combination of enteric-coated naproxen 500 mg and immediate-release esomeprazole magnesium 20 mg” PMID 21524238 ↗ Apr 2011 “esomeprazole magnesium enteric-coated tablets” NCT04034641 ↗ “Nexium (esomeprazole magnesium)” NCT01142128 ↗ “Esomeprazole magnesium (Nexium)” NCT00079833 ↗ “Esomeprazole magnesium (Nexium)” NCT00206024 ↗ “Drug: esomeprazole magnesium” NCT00687245 ↗ |
| Known as | Esomeprazole magnesium dihydrate | “Where treatment 1= Esomeprazole magnesium dihydrate 40 mg tablets test product, treatment 2= Esomeprazole magnesium dihydrate 40 mg tablets reference product.” NCT06233097 ↗1“Esomeprazole magnesium dihydrate 40 mg tablets Manufactured by: Cipla Limited, India” NCT06233149 ↗ |
| Known as | esomeprazole magnesium trihydrate | “The medication, esomeprazole magnesium trihydrate (40 mg), should be administered once a day (before breakfast) and the capsules should be taken on an empty stomach (orally)...” NCT01471925 ↗1“Pellets contains esomeprazole 20 mg (esomeprazole magnesium trihydrate 22.3 mg) and excipient granules filled into single-use aluminium sachets” NCT01964131 ↗ |
| Known as | Esomeprazole Mepha | “40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)” NCT00889850 ↗ |
| Known as | Esomeprazole Sodium | “Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours” NCT00428701 ↗1“Esomeprazole sodium for injection” NCT06783257 ↗ |
| Known as | esomprazole | “amoxicillin 1000 mg bid ,esomprazole 20 bid for one week then levofloxacine 500 mg q.d, metraonidazoel 500 500 bid, and esomprazole 20 bid for one week” NCT06065267 ↗ |
| Known as | Esso | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00520949 ↗ |
| Known as | Hanxium | “Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.” NCT02984930 ↗ |
| Known as | HGP1705 | “This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release esomeprazole) and HGP1705 (delayed-release esomeprazole) in patients with erosive esophagitis (EE).” PMID 38110901 ↗ Dec 2023 |
| Known as | HIP1601 | “This study aimed to compare the efficacy and safety of HIP1601 (dual delayed-release esomeprazole) and HGP1705 (delayed-release esomeprazole) in patients with erosive esophagitis (EE).” PMID 38110901 ↗ Dec 2023 |
| Known as | HIP2101 | “the dual delayed-release formulation of 10-mg esomeprazole (HIP2101) are currently limited” PMID 39949051 ↗ Feb 2025 |
| Known as | levofloxacine | “Drug stop within 24 hours after randomization:Piperacillin-tazobactam, amikacin, meropenem, cefepime, ceftazidime, vancomycin, teicoplanin, ciprofloxacin, levofloxacine and...” NCT07590648 ↗ |
| Known as | Nexium | “This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ®...” NCT00206050 ↗43“The purpose of this study is to evaluate whether there is a difference in proportion of patients with resolution of heartburn and other symptoms related to gastroesophageal...” NCT00242736 ↗ “The purpose of this study is to decide if controlling stomach acid is related to healing of erosive esophagitis after treatment with esomeprazole magnesium (NEXIUM®) 10 mg and...” NCT00206180 ↗ “One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks” NCT01107938 ↗ “After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.” NCT01822600 ↗ “Subjects to compare the single dose bioavailability of Torrent's Esomeprazole Mg DR Capsule 1×40 mg and Nexium 40 mg DR Capsule containing Esomeprazole 40 mg of AastraZeneca LP, USA.” NCT02680119 ↗ “Nexium® (Esomeprazole) gastro-resistant granules for oral suspension 10 or 20 mg taken once daily for 8 weeks, and then 10 or 5 mg taken once daily for 16 weeks.” NCT05267613 ↗ “The purpose of this research study is to measure the effects of the drug, esomeprazole 40 mg (Nexium) or placebo (inactive drug) on vocal cord granulomas.” NCT00567658 ↗ “The purpose of this study is to compare the efficacy of Nexium® with placebo in relief of acid related pain or discomfort in the chest.” NCT00251901 ↗ “Development of an Algorithm for Identification of Responders to Short Term Treatment With Esomeprazole (Nexium) in Primary Care” NCT00318968 ↗ “Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients” NCT00574925 ↗ “EsoduoⓇ (esomeprazole 20 mg with sodium bicarbonate 800 mg) or NexiumⓇ (esomeprazole 20 mg) once daily for 4 weeks” PMID 35730245 ↗ Jun 2022 “Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.” NCT03040817 ↗ “iv esomeprazole (Nexium® ) offers better intragastric acid suppression than iv lansoprazole (Prevacid ®” NCT00230516 ↗ “Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose” NCT01370538 ↗ “Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose” NCT01370525 ↗ “1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily” NCT01139645 ↗ “Nexium I.V. (Esomeprazole Sodium) 40mg BID for up to 72 Hours” NCT00428701 ↗ “esomeprazole, original Nexium, 40 mg pills Up to once a day” NCT00120315 ↗ “Esomeprazole (nexium, Tablets 20mg/tablet, 20mg bid)” NCT05586464 ↗ “Esomeprazole, nexium® 40 mg bid 10 days (D1-D10)” NCT02373280 ↗ “adminitration of Nexium tab 40mg, bid for 2weeks” NCT01761513 ↗ “proton pump inhibitors (ppi; Prevacid, Nexium).” NCT02794844 ↗ “Esomeprazole (Nexium) 20mg bid for 10 days” NCT01760824 ↗ “Nexium (esomeprazole), 40mg, bid, 14 days” NCT01725906 ↗ “Esomeprazole (Nexium) 40 mg/day” NCT00216788 ↗ “Esomeprazole magnesium (Nexium)” NCT00079833 ↗ “Esomeprazole magnesium (Nexium)” NCT00206024 ↗ “esomeprazole (Nexium®)” NCT00444275 ↗ “Esomeprazole - Nexium” NCT00998075 ↗ “NEXIUM (esomeprazole)” NCT00405119 ↗ “Esomeprazole (Nexium)” NCT00241501 ↗ “Esomeprazole (Nexium)” NCT00228527 ↗ “Nexium (esomeprazole)” NCT00303264 ↗ |
| Known as | Nexium (esomeprazole) | “Nexium (esomeprazole)” NCT02037477 ↗ |
| Known as | Nexium mups | “A 14-day regimen including proton pump inhibitor (PPI; esomeprazole \[Nexium MUPS\]), bismuth subcitrate (or bismuth subsalicylate), amoxicillin, and metronidazole.” NCT07260006 ↗1“esomeprazole (Nexium mups)” NCT06193811 ↗ |
| Known as | Tinadizole | “Levofloxacin 500 mg qd, amoxicillin 500 2cab bid,Tinadizole 500 bid, esomprazole 20 bid” NCT06065267 ↗1“Doxycylcine 100 mg bid ,esomprazole 20 bid,levofloxacineq.d,Tinadizole 500 bid” NCT04626193 ↗ |
| Action | Inhibit | “proton-pump inhibitor (PPI) therapy” PMID 25304129 ↗ Oct 2014 |
| Modality | Small molecule | “The proton pump inhibitor esomeprazole has been found to be effective for gastroprotection in NSAID users” PMID 23530709 ↗ Mar 2013 |
| Route | Oral | “Proton pump inhibitor 40 mg orally twice daily” NCT00069823 ↗ |